HIVE Blockchain Technologies (CVE:HIV – Get Free Report) was upgraded by equities researchers at Keefe, Bruyette & Woods to a “moderate buy” rating in a research note issued on Wednesday,Zacks.com reports.
HIV has been the topic of a number of other reports. Roth Capital raised shares of HIVE Blockchain Technologies to a “strong-buy” rating in a report on Wednesday, December 18th. Northland Capmk upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Thursday, September 19th. Finally, Cantor Fitzgerald upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Tuesday, October 29th. Four research analysts have rated the stock with a strong buy rating, According to MarketBeat, HIVE Blockchain Technologies currently has an average rating of “Strong Buy”.
Check Out Our Latest Analysis on HIV
HIVE Blockchain Technologies Price Performance
Read More
- Five stocks we like better than HIVE Blockchain Technologies
- With Risk Tolerance, One Size Does Not Fit All
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Read Stock Charts for Beginners
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Stock Sentiment Analysis: How it Works
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
